Johnson & Johnson Hits Big $360 Million Sweet Deal
In a showdown with the U.S. Justice Department, Actelion Pharmaceuticals US Inc., now a part of Johnson & Johnson, has agreed to pay a whopping $360 million (roughly S$493 million) to settle allegations that it used a charity to cover Medicare patients’ co‑pay bills. The settlement tops the chart of payments stemming from the government’s sweeping probe into how drug companies help patient‑assistance charities.
What Went Wrong?
- Wrongful Co‑Pay Artillery – From 2014 to 2015, Actelion allegedly funneled money through Caring Voice Coalition (CVC), a charity tasked with helping Medicare patients pay out‑of‑pocket costs for its own drugs: Tracleer, Ventavis, Veletri and Opsumit. Thousands of elderly patients got their co‑pays paid, but the trick was that drugmakers had too much influence over the charity.
- Regulatory Pull‑Back – In 2017, the Justice Department revoked CVC’s approval to receive pharma funding because of these concerns. Despite that, Actelion kept the flow of money flowing, saying the “big move was before J&J bought it in 2017.” The company promises to play by the rules from now on.
- No Admission of Guilt – Actelion’s spokesperson, Caroline Pavis, didn’t mention any wrongdoing. She’s basically saying, “We’re sorry for the past; we’re good now.” Meanwhile, CVC is staying tight‑lipped, refusing to comment on “ongoing legal matters.”
Why This Matters
Drug makers are forbidden from subsidizing co‑pays for Medicare enrollees. The only loophole is if a truly independent nonprofit receives the help. But the government suspects that these “independent” charities are actually dundee societies for the pharma giants, pushing drug sales up and, by extension, prices.
Other Big Players in the Whack‑Sam / Deductible Game
- Universally accused Prudently, United Therapeutics settled in 2017 over a $210 million payout relating to CVC.
- Pfizer settled for approximately $23.85 million after a similar chartered approach.
- Jazz Pharmaceuticals nailed a $57 million deal; Lundbeck walked away with $52.6 million.
What This Means for Patients
At its core, the settlement means better transparency and a promise to keep the needle from quivering. Patients will no longer be swayed by pharmaceutical slickness when it comes to out‑of‑pocket costs. The government’s crackdown will shut this practice down and hopefully put a stop to the hidden price hikes that have been lurking for years.
And for the big pharma hand, this is a warning: Don’t try to cheer up Medicare patients through a charity you pull the strings of; the legal and financial costs are bigger than any “co‑pay” you can offer. Whether you’re a casual cough‑or‑colchicine fan or a “pulmonary artery hypertension” expert, keep your charity independent or prepare for a serious reflection on FDA and Antibribery statutes.
